A short-term model for preliminary screening of potential anti-tubercular compounds

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 11-12, 2009, Pages 886-889

  Jhamb, Sarbjit Singh ^a   Singh, Prati Pal ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; ISONIAZID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; INCUBATION TIME; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SHORT COURSE THERAPY; TREATMENT DURATION; TUBERCULOSIS; VIRUS STRAIN;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FEMALE; FLUOROQUINOLONES; ISONIAZID; LUNG; MALE; MICE; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SPLEEN;

EID: 70450177645     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903214314     Document Type: Article

References (14)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006;/ 367:/938-40.
2. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005;/25:/ 928-936
3. Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med 2005;/11:/ 189-194
4. Jhamb SS, Singh RP, Singh PP. A comparison of conventional and radiometric methods for the assessment of antitubercular activity of drugs against Mycobacterium tuberculosis in mouse and macrophage models. Indian J Tuber 2008;/55:/70-6.
5. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;/40:/2809-12.
6. Singh RP, Jhamb SS, Singh PP. Effects of morphine during Mycobacterium tuberculosis H37Rv infection in mice. Life Sci 2008;/82:/308-14.
7. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;/49:/2294-301.
8. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003;/47:/783-5.
9. Nikonenko BV, Samala R, Einck L, Nacy C. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004;/48:/4550-5.
10. Shoen CM, DeStefano MS, Sklaney MR, Monica BJ, Slee AM, Cynamon MH. Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 2004;/53:/641-5.
11. Heifets LB, Iseman MD, Cook JL, Lindholm-Levy PJ, Drupa I. Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. Antimicrob Agents Chemother 1985;/ 27:/11-5.
12. Reddy M, Srinivasan S, Andersen B, Gangadharam P. Rapid assessment of mycobacterial growth inside macrophages and mice, using the radiometric (BACTEC) method. Tuber Lung Dis 1994;/75:/127-31.
13. Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004;/48:/2415-23.
14. Piddock LJ, Williams KJ, Ricci V. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J Antimicrob Chemother 2000;/45:/159-65. (Pubitemid 30095186)